We are live on ! Find out more
PCM

Penserra Capital Management Portfolio holdings

AUM $8.52B
1-Year Est. Return 37.76%
This Fund
S&P 500
This Quarter Est. Return
+16.8%
1 Year Est. Return
+37.76%
3 Year Est. Return
+116.32%
5 Year Est. Return
+122.1%
10 Year Est. Return
+1,892.45%
AUM
$2.63B
AUM Growth
+$690M
Cap. Flow
+$451M
Cap. Flow %
17.16%
Top 10 Hldgs %
21.75%
Holding
1,066
New
264
Increased
497
Reduced
181
Closed
122

Top Buys

Rank Stock Value
1
BABA icon
Alibaba
BABA
+$21.1M
2
MTCH icon
Match Group
MTCH
+$16.7M
3
AMZN icon
Amazon
AMZN
+$15.3M
4
MELI icon
Mercado Libre
MELI
+$13.9M
5
PDD icon
Pinduoduo
PDD
+$13.6M

Top Sells

Rank Stock Value
1
BBBY
Bed Bath & Beyond
BBBY
+$16M
2
PPLI
People Inc
PPLI
+$7.82M
3
ZM icon
Zoom
ZM
+$7.6M
4
KLAC icon
KLA
KLAC
+$7.1M
5
WUBA
58.com Inc
WUBA
+$6.96M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 35.11%
2 Technology 20.8%
3 Communication Services 14.79%
4 Industrials 4.05%
5 Financials 3.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SUPN icon
826
Supernus Pharmaceuticals
SUPN
$2.77B
$9K ﹤0.01%
+452
New +$10.3K
VNO icon
827
Vornado Realty Trust
VNO
$7.38B
$9K ﹤0.01%
272
+32
+13% +$1.14K
YRD
828
Yiren Digital
YRD
$110M
$9K ﹤0.01%
3,257
-4,201
-56% -$14.5K
NGM
829
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$9K ﹤0.01%
+588
New +$10.7K
ADVM
830
DELISTED
Adverum Biotechnologies
ADVM
$8K ﹤0.01%
+81
New +$12.1K
ATRA icon
831
Atara Biotherapeutics
ATRA
$76.1M
$8K ﹤0.01%
+25
New +$8.51K
CERS icon
832
Cerus
CERS
$474M
$8K ﹤0.01%
+1,418
New +$9.41K
CSTL icon
833
Castle Biosciences
CSTL
$979M
$8K ﹤0.01%
+168
New +$7.47K
ESPR
834
DELISTED
Esperion Therapeutics
ESPR
$8K ﹤0.01%
+236
New +$9.35K
LKFT
835
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
$8K ﹤0.01%
+62
New +$10.3K
GOSS icon
836
Gossamer Bio
GOSS
$87M
$8K ﹤0.01%
+648
New +$8.59K
MYGN icon
837
Myriad Genetics
MYGN
$312M
$8K ﹤0.01%
+638
New +$8.07K
RGNX icon
838
Regenxbio
RGNX
$708M
$8K ﹤0.01%
+320
New +$10.4K
RYTM icon
839
Rhythm Pharmaceuticals
RYTM
$7.96B
$8K ﹤0.01%
+378
New +$8.67K
TBPH icon
840
Theravance Biopharma
TBPH
$877M
$8K ﹤0.01%
+542
New +$10.2K
TVTX icon
841
Travere Therapeutics
TVTX
$5.78B
$8K ﹤0.01%
+434
New +$8.44K
ATNX
842
DELISTED
Athenex, Inc. Common Stock
ATNX
$8K ﹤0.01%
+35
New +$8.4K
TBIO
843
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$8K ﹤0.01%
+634
New +$9.77K
ZGNX
844
DELISTED
Zogenix, Inc.
ZGNX
$8K ﹤0.01%
+474
New +$11.6K
ALEC icon
845
Alector
ALEC
$199M
$7K ﹤0.01%
+676
New +$10.9K
AMPH icon
846
Amphastar Pharmaceuticals
AMPH
$916M
$7K ﹤0.01%
+404
New +$8.13K
ARVN icon
847
Arvinas
ARVN
$572M
$7K ﹤0.01%
+336
New +$9.74K
ENTA icon
848
Enanta Pharmaceuticals
ENTA
$400M
$7K ﹤0.01%
+170
New +$8.24K
FRT icon
849
Federal Realty Investment Trust
FRT
$10.3B
$7K ﹤0.01%
102
+12
+13% +$946
INGR icon
850
Ingredion
INGR
$6.58B
$7K ﹤0.01%
102
+12
+13% +$975
32 33
34
35 36

Similar funds

GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NB
Norinchukin Bank Tokyo, Japan $8.57B AUM 20.17% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACM
Advisors Capital Management Ridgewood, New Jersey $8.58B AUM 23.43% 1-Year Est. Return
FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Penserra Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Penserra Capital Management held 1,066 positions worth $2.63B, up 36% from $1.94B the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Penserra Capital Management deployed $451M of net new capital in Q3 2020, opening 264 new positions and adding to 497 existing holdings. Its largest new stake was Match Group: 157,606 shares worth $17.4M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 35% of assets, up from 29% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Bed Bath & Beyond, an estimated $16M trimmed.

  • Penserra Capital Management's largest Q3 2020 buy was Match Group: 157,606 shares worth $17.4M.
  • Penserra Capital Management added most to Alibaba in Q3 2020, an estimated $21.1M increase.
  • Penserra Capital Management's biggest Q3 2020 reduction was Bed Bath & Beyond, cutting an estimated $16M.
  • Penserra Capital Management fully exited 58.com Inc in Q3 2020, selling an estimated $6.96M.
  • Penserra Capital Management's ten largest holdings make up 22% of its $2.63B portfolio in Q3 2020.
  • Penserra Capital Management opened 264 new positions and closed 122 in Q3 2020.
  • Penserra Capital Management's portfolio value rose 36% quarter-over-quarter to $2.63B.

Based on Penserra Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.